The recent surge in capital into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for blockbuster treatments and impressive returns is clear, the connected risks are also notable. Many of these